Elsevier

Heart Rhythm

Volume 17, Issue 12, December 2020, Pages 2046-2055
Heart Rhythm

Clinical
Effect of QRS area reduction and myocardial scar on the hemodynamic response to cardiac resynchronization therapy

https://doi.org/10.1016/j.hrthm.2020.07.025Get rights and content

Background

Vectorcardiographic QRS area (QRSarea) predicts clinical outcomes after cardiac resynchronization therapy (CRT). Myocardial scar adversely affects clinical outcomes after CRT.

Objective

The purpose of this study in patients with an ideally deployed quadripolar left ventricular (LV) lead (QUAD) was to determine whether reducing QRSarea leads to an acute hemodynamic response (AHR) and whether scar affects this interaction.

Methods

Patients (n = 26; age 69.2 ± 9.12 years [mean ± SD]) underwent assessment of the maximum rate of change of LV pressure (ΔLV dP/dtmax) during CRT using various left ventricular pacing locations (LVPLs). Cardiac magnetic resonance (CMR) scan was used to localize LV myocardial scar.

Results

Interindividually, ΔQRSarea (area under the receiver operating characteristic curve [AUC] 0.81; P <.001) and change in QRS duration (ΔQRSd) (AUC 0.76; P <.001) predicted ΔLV dP/dtmax after CRT. Scar burden correlated with ΔQRSarea (r = 0.35; P = .003), ΔQRSarea (r = 0.35; P = .003), and ΔQRSd (r = 0.46; P <.001). A reduction in QRSarea was observed with LVPLs remote from scar (–3.28 ± 38.1 μVs) or in LVPLs in patients with no scar at all (–43.8 ± 36.8 μVs), whereas LVPLs over scar increased QRSarea (22.2 ± 58.4 μVs) (P <.001 for all comparisons). LVPLs within 1 scarred LV segment were associated with lower ΔLV dP/dtmax (–2.21% ± 11.5%) than LVPLs remote from scar (5.23% ± 10.3%; P <.001) or LVPLs in patients with no scar at all (10.2% ± 7.75%) (both P <.001).

Conclusion

Reducing QRSarea improves the AHR to CRT. Myocardial scar adversely affects ΔQRSarea and the AHR. These findings may support the use of ΔQRSarea and CMR in optimizing CRT using QUAD.

Introduction

Cardiac resynchronization therapy (CRT) is an established therapy for patients with impaired left ventricular (LV) systolic function and a wide QRS complex. In addition to improving symptoms and quality of life, CRT reduces heart failure hospitalizations and improves survival.1 However, even in guideline-indicated patients, the response to CRT is variable. The nonresponder rate ranges between 9% and 68%, depending on the criteria used to define response.2 Prominent among the factors implicated in nonresponse is suboptimal LV lead deployment.

Quadripolar LV leads (QUAD) have been a game-changer in the field of CRT. The availability of a wide range of left ventricular pacing locations (LVPLs) not only reduces diaphragmatic stimulation but also permits LV pacing from widely spaced areas of the myocardium. Several studies have shown that optimizing LVPLs on a QUAD in individual patients improves the acute hemodynamic response (AHR) to CRT.3,4 Myocardial scar in the vicinity of the LVPL has been shown to be detrimental in studies using bipolar leads,5,6 but no studies have explored whether the same applies to QUAD.

It has been shown recently that vectorcardiography (VCG)-derived QRS area (QRSarea) is a measure of LV electrical dyssynchrony, the natural substrate of CRT.7 Moreover, QRSarea has been shown to correlate with AHR8,9 and LV reverse remodeling10 after CRT. A reduction in QRSarea has been shown to improve AHR to CRT in patients with suboptimal LV lead deployment.11 Importantly, preimplant QRSarea has been shown to be superior to QRS duration (QRSd) in predicting total mortality after CRT.12,13 We recently showed that a postimplant reduction in both QRSarea and QRSd was associated with the best outcomes after CRT.14 In the present study, we explored whether in patients with an optimally deployed LV lead assessed by fluoroscopy, a change in QRSarea (ΔQRSarea) after CRT relates to AHR; AHR in individual patients can be improved by reducing QRSarea; and AHR relates to the position of the LVPL in relation to myocardial scar, assessed using cardiac magnetic resonance (CMR).

Section snippets

Methods

A total of 26 patients referred for CRT implantation at the University Hospital Birmingham, United Kingdom, were studied. All patients provided written informed consent. The study was approved by the regional ethics committee and conformed with the Declaration of Helsinki.

Baseline characteristics

A total of 4 of 30 patients (13.3%) who had been enrolled were excluded because of second-degree atrioventricular block during atrial (AAI) pacing in 1; frequent ventricular ectopics in 1; and LV thrombus noted on CMR in 2. Among the 26 patients included (age 69 ± 9.1 years; 20/26 [77%] male), the underlying etiology was ICM in 17 (65%) (Table 1). Left bundle branch block (LBBB) was present in 20 patients (76.9%) and non-LBBB in 6 (23.1%) (5 nonspecific intraventricular conduction delay; 1

Discussion

Several findings have emerged regarding the optimization of LVPLs in CRT recipients who have a fluoroscopically ideal LV lead position. First, altering LVPLs on a QUAD was associated with wide intraindividual variations in LV dP/dtmax, QRSarea, and QRSd. Second, ΔQRSarea correlated with ΔLV dP/dtmax across LVPLs. Third, both myocardial scar burden and location of scar in the vicinity of the LVPL had a negative effect on AHR to CRT.

Conclusion

We have shown that in patients with an ideally deployed LV lead, optimizing LVPLs on a QUAD to achieve maximum QRSarea reduction leads to the best AHR to CRT. Both myocardial scar burden and location of scar in the vicinity of the LVPL had a negative effect on AHR to CRT. These findings have implications for the use of QRSarea and CMR in CRT optimization.

References (21)

There are more references available in the full text version of this article.

Cited by (0)

Funding sources: There are no funding sources other than those listed in Disclosures below.

Disclosures: Dr Okafor was supported by an unrestricted educational grant from Medtronic Plc. Dr van Dam is owner of PEACS. Dr Leyva has received consulting fees and research sponsorship from Medtronic Plc, Boston Scientific, Abbott, Biotronik, and Microport. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

View full text